MyFinsight

HomeBlogAboutContact

MyFinsight

Making company financials insightful for everyone

Quick Links

  • About
  • Blog
  • Contact

Follow Us

  • X.com
  • Thread
  • Instagram

© 2026 MyFinsight. All rights reserved.

DownloadDownload image
US$800,382K Non Us$165,183K Revenue From ContractWith Customer...$898,731K Net (loss) income-$713,410K (-403.27%↓ Y/Y)Pmo Products$965,565K Elevidys$898,731K (loss) income beforeincome tax expense-$702,225K (-369.28%↓ Y/Y)Income tax expense$11,185K (-56.20%↓ Y/Y)Products, net$1,864,296K (4.27%↑ Y/Y)Collaboration and other$333,941K (192.88%↑ Y/Y)Operating (loss) income-$699,781K (-420.88%↓ Y/Y)Total other (loss)income, net-$2,444K (-105.72%↓ Y/Y)Total revenues$2,198,237K (15.58%↑ Y/Y)Gain (loss) on debtextinguishment$16,862K Total cost andexpenses$2,898,018K (72.10%↑ Y/Y)Other (expense)income, net-$19,306K (-145.22%↓ Y/Y)Research and development$1,522,066K (89.19%↑ Y/Y)Cost of sales(excluding amortization of...$839,605K (163.12%↑ Y/Y)Selling, general andadministrative$491,716K (-11.86%↓ Y/Y)Restructuring charge$42,009K Amortization of in-licensedrights$2,622K (9.02%↑ Y/Y)
Income Statement
source: myfinsight.com
logo (1) copy-svg

Sarepta Therapeutics, Inc. (SRPT)

logo (1) copy-svg

Sarepta Therapeutics, Inc. (SRPT)